ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Stock Information for ASLAN Pharmaceuticals Limited

Loading

Please wait while we load your information from QuoteMedia.